Bempedoic acid is a first-in-class adenosine triphosphate-citrate lyase (ACL) inhibitor that lowers LDL-C by inhibiting cholesterol synthesis in the liver.
Treatment with evolocumab was found to be effective in reducing plasma levels of low-density lipoprotein cholesterol in familial hypercholesterolemia.
The increased mortality rate in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy is mostly related to endocrine and metabolic diseases, infections, and oral and esophageal malignancies.
Treatment with statins is not associated with increased risk for ICH in patients with a history of stroke, and may even decrease the risk for ICH in some of these patients.
Among other strategies, clinicians can suggest changes to lifestyle habits, encourage sleep hygiene, and prescribe pharmacologic interventions to combat risk for metabolic syndrome in shift workers.
Machine learning identifies factors related to obesity, dyslipidemia, and inflammation as predictors of noncalcified coronary burden in patients with psoriasis, a study finds.
The FDA has granted Orphan Drug designation to setmelanotide (Rhythm Pharmaceuticals) for the treatment of Alström Syndrome.
Early markers of cardiovascular and metabolic disease were elevated in adolescents with psoriasis, despite early disease.
Metabolic syndrome, including hypertension, obesity, dyslipidemia, and hyperglycemia, promote arterial stiffness, which has been linked to depression.
While current cardiovascular risk scores can identify subclinical vascular damage in people living with HIV, they fail to predict progression of such damage.
Dapagliflozin was found to lower the risk for worsening heart failure or death in patients with heart failure and reduced ejection fraction, and with or without diabetes compared with placebo.